[1] Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma:the current consensus[J]. Acta Neuropathol, 2012, 123(4):465-472. [2] Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine ki-nase:a crucial player in diverse biological functions[J]. Nat Rev Immunol, 2010, 10(6):387-402. [3] Coopman PJ, Mueller SC. The Syk tyrosine kinase:a new negative regulator in tumor growth and progression[J]. Can-cer Lett, 2006, 241(2):159-173. [4] Momparler RL, CØté S, Momparler LF, et al. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycyti-dine (decitabine) in combination with inhibitors of histone methylation and deacetylation[J]. Clin Epigenetics, 2014, 6(1):19. [5] Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine[J]. Nat Rev Drug Discov, 2005, 4(4):275-276. [6] Sada K, Takano T, Yanagi S, et al. Structure and function of Syk protein-tyrosine kinase[J]. J Biochem, 2001, 130(2):177-186. [7] Yuan Y, Mendez R, Sahin A, et al. Hypermethylation leads to silencing of the Syk gene in human breast cancer[J]. Cancer Res, 2001, 61(14):5558-5561. [8] Yang Z, Huo L, Chen H, et al. Hypermethylation and prog-nostic implication of Syk gene in human colorectal cancer[J]. Med Oncol, 2013, 30(2):586-588. [9] Peng C, Sun Q, Hao Y, et al. Syk is low-expressed in non-small-cell lung cancer and inversely correlates with patient's survival[J]. Acta Biochim Biophys Sin, 2013, 45(2):149-151. [10] Layton T, Stalens C, Gunderson F, et al. Syk tyrosine ki-nase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth andinvasion[J]. Am J Pathol, 2009, 175(6):2625-2636. [11] Carter WB, Hoying JB, Boswell C, et al. HER2/neu over expression induces endothelial cell retraction[J]. Int J Can-cer, 2001, 91(3):295-299. [12] 张楹恬, 田卫平, 梅玫. miR-21与DNA甲基化在不同乳腺癌细胞中的相互作用[J]. 中国应用生理学杂志, 2015, 31(3):220-224. |